Wuxi Saibiman Biotechnology

Wuxi Cybiman Biotechnology is a clinical-stage biopharmaceutical company based in Wuxi, China, specializing in the development of innovative cell therapies for cancer and autoimmune disorders. The company focuses on engineering chimeric antigen receptor (CAR) T-cells and Natural Killer (NK) cells, leveraging a proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf treatments. Their lead candidate, CBM-G01, is a CAR-T therapy targeting GPC3 for the treatment of hepatocellular carcinoma, currently in Phase 1 clinical trials. Cybiman also maintains a pipeline of therapies targeting hematological malignancies, including CD19 and BCMA directed programs. By integrating advanced gene editing and cell reprogramming technologies, the company aims to improve the efficacy and accessibility of cell-based immunotherapies. Cybiman is strategically located in the Wuxi International Life Science Innovation Campus and has received significant backing from the AstraZeneca-CICC Fund.